Company profile
Amneal Pharmaceuticals, Inc.
NASDAQ: AMRX · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Bridgewater, NJCIK 0001723128Reports USD
#87 of 1,418 Healthcare companies by revenue53rd-percentile growth
EA Score
75B+FH 86DQ 61GM 69SS 75
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, growth stability · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$3.0B
Rev growth YoY (TTM)
+7.6%
Net income (FY)
$72.1M
Employees
8,500
as of 2026-08-07
Market cap
$5.8B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.0B$3.0B2025
Net income$72.1M$72.1M2025
Operating income$394.1M$394.1M2025
Total assets$3.7B$3.7B2025
Liabilities$0$02017
Equity-$70.8M-$70.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Specialty100%
By geography
Specialty100%
The read
What is Amneal Pharmaceuticals, Inc.’s revenue?
Amneal Pharmaceuticals, Inc. booked $3.0B in FY2025 revenue, growing 8.0% year over year — about the middle of the pack among Healthcare companies we track, at a 2.4% net margin.
Peers · Healthcare
Waters Corporation82B+MiniMed Group, Inc. Common Stock73BWest Pharmaceutical Services, Inc.86AGlobus Medical, Inc.86ANeurocrine Biosciences, Inc.88ARevvity, Inc.79B+Key facts
CEOChirag K. Patel
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBridgewater, NJ
ExchangeNASDAQ: AMRX
Employees8,500
IPO date2018-05-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.